Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants

被引:49
作者
Barbaro, Danielle
Boni, Giuseppe
Meucci, Giuseppe
Simi, Umberto
Lapi, Paola
Orsini, Paola
Pasquini, Cristina
Turco, Anna
Mariani, Giuliano
机构
[1] Spedali Riuniti Livorno, Endocrinol Sect, I-57100 Livorno, Italy
[2] Univ Pisa, UO Nucl Med, Pisa, Italy
关键词
rhTSH; differentiated thyroid cancer; radiometabolic treatment;
D O I
10.1097/00006231-200608000-00005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate whether recombinant human thyroid-stimulating factor (rhTSH) is effective for the radiometabolic ablation of post-surgery thyroid remnants, using low doses of I-131. Patients and methods The study included two groups of patients enrolled consecutively: group 1 consisted of 52 patients with papillary cancer or minimally invasive follicular cancer (stage I and 11), and group 2 consisted of 41 patients with the same stage of disease. All patients underwent a total thyroidectomy. Group 1 received 1.11 GBq (30 mCi) I-131 for post-surgical remnants ablation with the aid of rhTSH, while group 2, in the hypothyroid state, received the same amount of radioiodine. To minimize iodine interference, all patients remained on a low iodine diet for 2 weeks and L-thyroxine (L-T4) was stopped for 4 days in the group of patients treated with the aid of rhTSH. To investigate I-131 uptake in this group, a tracer dose was administered 3 h after the second injection of rhTSH and the uptake was evaluated at 24 h just before administration of the therapeutic dose. I-131 was also measured in the patients treated in the hypothyroid state just before the therapeutic dose was given. Results After 1 year both groups were studied by using whole-body scintigraphy (WBS) and measuring thyroglobulin after rhTSH. In group 1, WBS was negative in 76.9% (40 patients), while thyroglobulin-stimulated levels were < 1.0 ng(.)ml(-1) in 86.5% (45 patients). In Group 2, WBS was negative in 75.6% (31 patients), while thyroglobulin-stimulated levels were < 1 ng(.)ml(-1) in 78.0% (32 patients). I-131 uptake was 2.29 +/- 0.45 in the group treated with the aid of rhTSH, and 3.30 +/- 0.7 in the group treated in the hypothyroid state (P=0.2). No patients treated with the aid of rhTSH and with the short stoppage of L-T4 experienced symptoms of hypothyroidism, and free thyroxine (FT4) and thyroid-stimulating hormone levels remained normal. Conclusions Our data confirm that, when the interference of iodine is minimized, rhTSH is highly effective for the treatment of post-surgical thyroid remnants using a low dose of I-131.
引用
收藏
页码:627 / 632
页数:6
相关论文
共 23 条
  • [1] Adler M L, 1998, Endocr Pract, V4, P282
  • [2] Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation
    Barbaro, D
    Boni, G
    Meucci, G
    Simi, U
    Lapi, P
    Orsini, P
    Pasquini, C
    Piazza, F
    Caciagli, M
    Mariani, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) : 4110 - 4115
  • [3] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    Berg, G
    Lindstedt, G
    Suurküla, M
    Jansson, S
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) : 44 - 52
  • [4] Prognosis and treatment of brain metastases in thyroid carcinoma
    Chiu, AC
    Delpassand, ES
    Sherman, SI
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (11) : 3637 - 3642
  • [5] de Keizer B, 2004, J NUCL MED, V45, P1549
  • [6] NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA
    DEGROOT, LJ
    KAPLAN, EL
    MCCORMICK, M
    STRAUS, FH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) : 414 - 424
  • [7] Duick Daniel S, 2003, Endocr Pract, V9, P204
  • [8] Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells
    Kogai, T
    Endo, T
    Saito, T
    Miyazaki, A
    Kawaguchi, A
    Onaya, T
    [J]. ENDOCRINOLOGY, 1997, 138 (06) : 2227 - 2232
  • [9] Löffler M, 2003, NUKLEARMED-NUCL MED, V42, P240
  • [10] MARUCA J, 1984, J NUCL MED, V25, P1089